Violich Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Violich Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,200	Closed	-$242K	–	127
2021 Q2	$242K	Hold	1,200	–	–	0.04%	101
2021 Q1	$258K	Hold	1,200	–	–	0.05%	94
2020 Q4	$284K	Sell	1,200 -100	-8%	-$22.9K	0.05%	89
2020 Q3	$354K	Hold	1,300	–	–	0.07%	79
2020 Q2	$377K	Hold	1,300	–	–	0.08%	82
2020 Q1	$309K	Buy	+1,300	New	+$298K	0.08%	81

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Violich Capital Management's VRTX Position: Q3 2021 in Review

Violich Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 1,200 shares — an estimated $242K sold.

Violich Capital Management first reported a position in VRTX in Q1 2020 and held it in 6 quarters. The position peaked at $377K in Q2 2020. 934 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Violich Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Violich Capital Management sold 1,200 Vertex Pharmaceuticals shares in Q3 2021, an estimated $242K.
Violich Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Violich Capital Management's Vertex Pharmaceuticals position peaked at $377K in Q2 2020.
934 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Violich Capital Management's 13F filing for Q3 2021, filed 12 Oct 2021.